e have examined whether primary human muscle-derived cells can be used in ex vivo gene therapy to deliver BMP-2 and to produce bone in vivo. Two in vitro experiments and one in vivo experiment were used to determine the osteocompetence and BMP-2 secretion capacity of cells isolated from human skeletal muscle.
Delivery of exogenous growth factors is hindered by onetime dosing, dilution of the growth factors by body fluids, the short half-life of the protein (t 1/2 < 0.1 days, but it can be altered by impregnation on to carriers), 1, 2 and the need for a scaffold on which to impregnate the growth factor. Consequently, researchers have begun to investigate methods using gene therapy to deliver bone morphogenetic protein-2 (BMP-2). [3] [4] [5] [6] [7] [8] [9] [10] [11] There are few published reports of gene delivery of BMP-2, but both direct (in vivo) 3, 10 and ex vivo [4] [5] [6] [7] [8] [10] [11] [12] approaches have proved to be feasible. The in vivo approach is attractive because of its technical simplicity but is limited by concerns as to in vivo genetic manipulation and the introduction of attenuated viral vectors. The ex vivo approach circumvents these concerns by confining genetic manipulation to the culture flask, thereby allowing safety testing before the introduction of the cells into the patient. However, it requires technical expertise and effort to isolate cells in vitro, to transduce or transfect the cells with the desired vectors (viral and non-viral), and to inject the genetically-engineered cells into the patient. Some investigators have reduced this technical complexity by using immortalised cell lines from rats, thereby eliminating the need to isolate primary cells from the organism. 6 Although this technique is conducive to laboratory research, it is not clinically applicable because immortalised cell lines often have tumorigenic potential and are either allogeneic or xenogeneic to the patient. The cell type to be used in a given application should depend on the availability of a tissue for biopsy, the ease of isolation of a particular cell type and its osteocompetence. The last has been demonstrated in cells derived from skeletal muscle isolated from both animals 5, [12] [13] [14] and man. 15 Skeletal muscle is readily available to orthopaedic surgeons. Primary skeletal cells can be reliably isolated from rodents using previously described techniques. 16, 17 Murine skeletal muscle cells have been successfully used in ex vivo gene delivery of BMP-2 and respond to the secreted BMP-2 in an autocrine manner to contribute to in vivo bone formation. 5, 11, 12 Therefore cells isolated from human skeletal muscle may represent an attractive cell population on which to base the use of BMP-2 gene therapy to improve bone healing.
Our study was designed to investigate the hypothesis that primary human muscle cells can be used in ex vivo gene therapy to deliver BMP-2 and to produce bone in vivo. The study consisted of two in vitro experiments and one in vivo experiment. The first in vitro experiment tested the hypothesis that cells isolated from human skeletal muscle are responsive to BMP-2 stimulation, suggesting osteogenic differentiation. The second examined whether cells isolated from human skeletal muscle could be transduced to secrete BMP-2 by an adenoviral factor carrying the BNP-2 gene. The in vivo experiment tested the hypothesis that cells isolated from human skeletal muscle could be successfully used in an ex vivo gene-transfer approach to deliver BMP-2 in vivo and to induce bone formation. In this experiment, the cells were also transduced with a retrovirus encoding for a nuclear localised ␤-galactosidase gene, which allowed identification of the injected cells in histological specimens. Identification of the BMP-2-secreting human musclederived cells provided information regarding the role of these cells in the induced bone formation.
Materials and Methods
Cell isolation. Skeletal muscle biopsies (~1 to 2 g) were obtained from three human subjects at the time of surgery. The described procedure was approved by the institutional review board and the research protocol was reviewed and approved by the Animal Research and Care Committee at the Children's Hospital of Pittsburgh and the University of Pittsburgh. The specimens were placed on ice in Hanks's balanced salt solution (HBSS) (Gibco BRL, Grand Island, New York) and transferred to the laboratory. Musclederived cells were isolated using the preplate technique, which isolates cell populations based on their differential adhesion characteristics to collagen-coated flasks. 16, 17 Briefly, the tissue was finely minced by scalpel blades and then serially digested with 0.2% collagenase, 0.25% dispase, and 0.1% trypsin, each for one hour. The cells were then suspended in MCDB 131 medium supplemented with 10% fetal bovine serum (FBS), 10% horse serum, and 1% penicillin/streptomycin, and mechanically dissociated by serial passages through 18-, 21-and 23-gauge needles. The resultant cell suspension was placed in a collagen-coated flask (preplate (ppl) 1). After one hour, non-adherent cells were transferred to a fresh collagen-coated flask (ppl 2) and then 24 hours later those in the second preplate were transferred to another fresh collagen-coated flask (ppl 3). This procedure was repeated until ppl 5 was obtained. Forty-eight hours after the creation of each ppl, the medium was discarded and fresh medium was placed on the adherent cells. Five ppls were created because cell numbers decreased dramatically after ppl 3. It was felt that the yield of cells in any ppls beyond ppl 5 would be negligible and would require extensive cell-culturing time to obtain the adequate density of cells required for this experiment.
The cells in each ppl were cultured at 37°C, with change of medium every 48 hours until adequate cell numbers were obtained. Once this had occurred the cells were immediately used in all three experiments simultaneously, ensuring that the cell populations tested in each experiment were the same. Desmin, a myogenic marker, has been used to differentiate fibroblast and myogenic cells in musclederived cells isolated from mice and the findings suggest that fibroblast-type cells tend to adhere to a collagen-coated flask rapidly. 16, 17 Fibroblasts therefore tend to be isolated in the first ppl. Myogenic cells tend to adhere later to a collagen-coated flask and therefore are isolated in later ppls. 16, 17 We used the ppl technique to determine whether the different populations of cells isolated from human skeletal muscle had discrete characteristics in terms of responsiveness as well as delivery of BMP-2, similar to that observed in rodents. 5, 11, 12 The in-depth characterisation of the cell types in each ppl obtained from human skeletal muscle is the subject of ongoing work in our laboratory.
Desmin immunohistochemistry on muscle cells in vitro.
Cells were plated in a six-well culture dish and fixed with cold methanol for one minute. After rinsing with phosphate-buffered saline (PBS), they were blocked with 5% horse serum at room temperature for one hour. The mouse anti-desmin antibody (1:100, Sigma, St Louis, Missouri) was used as the primary antibody and was diluted in PBS. A biotinylated secondary antibody (anti-mouse) was applied for one hour at room temperature. The cells were finally rinsed with PBS, then incubated at room temperature with 1/300 streptavidin conjugated with Cy3 fluorochrome (Sigma) for one hour. 5 They were visualised by fluoroscopy, and the percentage of positive cells calculated by counting positively stained cells in ten randomly chosen 20ϫ fields. In vitro osteocompetence. We assessed in vitro osteogenic responsiveness to rhBMP-2 by quantification of the production of alkaline phosphatase. On day zero, 7.5 ϫ 10 3 cells from each ppl were plated in 12-well plates. The cells were allowed to adhere to the plate for 24 hours before stimulation with rhBMP-2. The medium was then removed, each well was washed briefly with HBSS, and 500 l of fresh medium were added to each well. Four wells for each cell population received medium containing 200 ng/ml of rhBMP-2 (Genetics Institute, Cambridge, Massachusetts) and four control wells for each cell population had medium without rhBMP-2. The medium changes were repeated 48 and 96 hours later to ensure adequate concentrations of rhBMP-2. The cells were harvested 24 hours after the last medium change and counted. Cell lysates were created using sterile distilled water in serial freeze-thaw cycles to release the cell-bound alkaline phosphatase. The latter catalyses the reaction between p-nitrophenyl phosphate and water, releasing p-nitrophenol and phosphate. The activity of alkaline phosphatase was detected by recording the change in optical density induced by this reaction using a commercially available kit (Sigma). The data were expressed in international units per litre per 1 ϫ 10 6 cells and underwent statistical analysis (Student's t-test, two-tailed, unequal variances).
Construction of viral vector.
A plasmid containing BMP-2 cDNA was provided (Genetics Institute) for construction of replication-defective adenoviral vector, E1 and E3 genes deleted, to encode for BMP-2 under control of the human cytomegalovirus (HCMV) promoter. Briefly, a BMP-2-125 plasmid was digested with the restriction enzyme Sal I, allowing isolation of the 1237 base pair (bp) fragment containing the entire hBMP-2 cDNA. This was inserted into the Sal I site of the pAd.lox plasmid such that the translation start site was adjacent to the HCMV promoter. Recombinant adenovirus was then obtained by cotransfection of pAd.lox with psi-5 viral DNA into CRE-8 cells as previously described. 18 The adenovirus-BMP-2 construct (AdBMP-2) was stored at -80°C. In vitro secretion of BMP-2. In vitro secretion of BMP-2 after AdBMP-2 transduction was quantified for the cells in each of the five ppls. From each ppl 7.5 ϫ 10 3 cells were plated in triplicate in 12-well plates. For each different cell population from the different preplates, the cells in the first well were incubated in solution containing AdBMP-2 (experimental cells), those in the second well were not exposed to AdBMP-2 (control), and those in the third well were used for counting. To calculate the amount of AdBMP-2 needed the cells were allowed to adhere to the plate for 24 hours before infection with AdBMP-2. The medium (Dulbecco's minimum essential medium supplemented with 10% FBS and 1% penicillin/streptomycin) from each well was removed, and the well was washed twice with HBSS. The experimental cells were incubated for three hours in 500 l of HBSS containing AdBMP-2 at a multiplicity of infection of 50 (MOI = 50). The control cells were incubated for three hours in 500 l of HBSS without AdBMP-2. After three hours, 1 ml of medium was added to each well. The cells were then left undisturbed for 72 hours. The supernatants from the experimental and control wells were harvested and frozen at -80°C, and the cells were counted. The amount of BMP-2 in the supernatants was determined by enzyme-linked immunosorbent assay (ELISA). The samples were incubated in a 96-well plate overnight at 4°C. The wells were then washed and blocked with non-fat milk protein for six hours at room temperature. The samples underwent three washes with PBS/0.05% Tween 20. The primary mouse monoclonal anti-BMP-2 antibody (Genetics Institute), diluted in non-fat milk and Gey's balanced salt solution (GBSS), was added and the plate incubated at room temperature for four hours. After a thorough wash, the secondary goat anti-mouse antibody, conjugated to horseradish peroxidase (HRP) (Southern Biotechnology Associates Inc, Birmingham, Alabama), was added, and the plate was incubated at room temperature for four hours. After washing, hydrogen peroxide substrate was added to each well. The reaction was stopped with sulphuric acid, and the change in optical density recorded at 450 nm. Included in the ELISA were negative control wells containing just medium or just GBSS, as well as positive control wells containing known concentrations of rhBMP-2 to establish a standard curve. The production of BMP-2 was determined by comparison with this standard curve. Ex vivo gene therapy to produce in vivo bone. Cells from each of the five ppls were pooled to recreate a mixed population of cells as would be obtained by simple primary cell culture. These were cultured in 75 cm 2 flasks in preparation for viral infection and subsequent injection into the animals. We used a retroviral vector encoding for a nuclear localised ␤-galactosidase enzyme (retroviral lacZ) which when exposed to X-gal substrate, results in blue staining of the nuclei of the transduced cells allowing their identification in histological specimens. 5, 11, 12 Two days before injection, the cells were washed with HBSS and then incubated in 4 ml of retroviral lacZ (1 ϫ 10 7 colony-forming units (CFU) and 8 l of polybrene. After four hours of incubation at 37°C, 10 ml of medium were added, and the cells were allowed to recover for 24 hours. Uninfected cells in corresponding 75 cm 2 flasks were then counted. Those previously infected with retroviral lacZ were washed twice with HBSS. The cells were then bathed in 10 ml of HBSS containing sufficient AdBMP-2 to achieve an MOI of 50. Retrovirally-infected control cells did not undergo infection with AdBMP-2. Medium was added after six hours of incubation at 37°C. The cells were allowed to recover for 18 hours, then trypsinised, and 2 ϫ 10 6 cells were suspended in 30 l aliquots of HBSS. The retroviral lacZ/AdBMP-2-infected cell populations were injected into the triceps surae of 12 adult severe combined immune-deficient (SCID) mice under methoxyflurane anaesthesia. Twelve separate animals received injections into the triceps surae of the control retroviral lacZ-infected cell suspensions. A No. 11 scalpel blade was used to make a skin incision 3 mm long in the posterior hind limb. Injections were performed using a gas-tight syringe (Hamilton Co, Reno, Nevada). One 4-0 silk suture was used to close the skin. The animals were allowed water, food and activity ad libitum.
Three animals (six limbs) from both the experimental and control groups were killed at 1, 2, 3 and 4 weeks after injection. They were anaesthetised with methoxyflurane and killed by cervical dislocation. The hind limbs were harvested and radiographs were obtained. The posterior hind-limb musculature was dissected from the limb and flash frozen in 2-methylbutane precooled with liquid nitrogen. The specimens were stored at -80°C until sectioning. A cryostat was used to make 10 m thick muscle sections in quadruplicate. All slides were fixed for one minute in 1% glutaraldehyde. One slide was incubated for 12 hours in Xgal substrate to reveal the location of the injected cells as previously described. 5, 11, 12, 19 Corresponding slides were stained with Alcian Blue, haematoxylin and eosin, and von Kossa's stain. All animal procedures were approved by the institution's Animal Research and Care Committee.
Results
In vitro osteocompetence. Desmin, a myogenic marker, was used to investigate the percentage of myogenic cells in the various cell populations. 16, 17 The desmin immunoreactivity of these cells (ppl to pp5) showed that 57% of the cells in ppl 1, 63% of those in ppl 2, 83% of those in ppl 3, 51% of those in ppl 4, and 61% of those in ppl 5 were desmin-positive. These results suggest that ppl 3 contained more desmin-positive cells (myogenic cells) than any of the other ppl populations. All cell populations isolated from skeletal muscle responded to rhBMP-2 by producing more alkaline phosphatase (U/l/million cells) than their non-stimulated controls (Fig. 1) . The mean levels (95% confidence intervals) of alkaline phosphatase for BMP-2-stimulated and unstimulated cells, respectively, were 24.65 (22.19 (Fig. 4) . A transition zone including hypertrophic chondrocytes, calcified cartilage matrix and calcified bone was present at one week after injection (Figs 4a, 4e and 4i). Cartilage, stained blue by Alcian Blue, was decreasing at two weeks after injection (Fig. 4f) and was non-existent at three (Fig. 4g) (Fig. 4j, black arrow) . The There is endochondral ossification at one week, including hypertrophic chondrocytes (Fig. 4i, black arrowheads) , calcified cartilage matrix (Fig. 4a, white arrow) and mineralised bone (Figs 4a and 4e, white arrowheads). A small amount of cartilage (Fig. 4f, blue staining) persists at two weeks after injection. There is cell collection (Fig. 4j, black arrow) surrounding ectopic bone and infiltrating myofibres. Mineralised bone (Fig. 4c, black staining) surrounding trabecular spaces presented three weeks after injection. viral transduction of human muscle-derived cells with a retroviral lacZ vector facilitated identification of the injected cells in histological specimens. In vitro staining for ␤-galactosidase demonstrated a transduction efficiency of 25% resulting from the retroviral infection. Staining for ␤-galactosidase showed that none of the labelled cells was present in the cartilage of the endochondral ossification process (Fig. 5a ). Labelled cells, however, were identified lining the ectopic bone, locations normally occupied by osteoblasts (Fig. 5b, arrow) . These data suggested that some of the human muscle-derived cells responded to the secreted BMP-2 and entered an osteoblastic lineage. Injection of human muscle-derived cells not transduced by AdBMP-2 into SCID mice hind-limb musculature did not produce histologically or radiographically detectable ectopic bone at any time period (Fig. 3) , confirming that secretion of BMP-2 was the critical bone-inducing stimulus.
Discussion
Our study supports the hypothesis that human musclederived cells may be used in a method of ex vivo gene therapy to deliver BMP-2. The in vitro data on alkaline phosphatase indicated that the cells isolated in separate ppls responded in different degrees to stimulation by BMP-2 ( Fig. 1) . This suggested that certain cells derived from human skeletal muscle may undergo osteogenic differentiation in response to BMP-2 and that the separate ppls appear to contain different cell populations. The in vitro ELISA data confirmed that human skeletal-muscle-derived cells may be transduced by an adenoviral vector to secrete BMP-2 ( Fig. 2) and that AdBMP-2-transduced human muscle-derived cells are capable of secreting sufficient quantities of BMP-2 to induce formation of bone in vivo (Figs 3  and 4) . Identification of the injected cells by staining of ␤-galactosidase provided further evidence that certain transduced human muscle-derived cells respond to the secreted BMP-2 by differentiating into osteoblasts (Fig.  5) .
Both in vitro experiments provided useful information for choosing which cell population to use in BMP-2 gene therapy applications. The desmin-rich cells in ppl 3 were the most BMP-2 responsive and therefore would be expected to be the most osteogenic in response to BMP-2 (Fig.  1) . These cells may be analogous to the desmin-positive murine pluripotent cells capable of myogenic and osteogenic differentiation described in previous studies. 5, 12 The cells in ppl 1 secreted the largest quantities of BMP-2 after transduction of AdBMP-2, suggesting that ppl 1 cells may be optimal for delivery of BMP-2 (Fig. 2) . Most fibroblasts, which adhere quickly to the collagen-coated flask, are expected to be in the first ppl, which contains a low percentage of desmin-positive cells. 16, 17 Fibroblasts have been shown in previous studies to be unresponsive to BMP-2, but capable of BMP-2 gene delivery. 11 It is not possible to determine from this study why the cells in ppl 1 produced more BMP-2 when transduced by AdBMP-2. One possibility is the tendency of fibroblasts to be hardy cells, which may have improved survival after viral infection. Another is that fibroblasts may be inherently efficient at the secretion of extracellular protein. Photomicrographs of hind limbs two weeks after injection with human muscle-derived cells transduced to express BMP-2. The sections are stained for ␤-galactosidase and counterstained with eosin to identify retrovirally labelled cells (blue). There are no labelled cells in the cartilage of endochondral bone (Fig. 5a ). Labelled human muscle-derived cells were found lining ectopic osteoid (Fig. 5b, black arrow) , locations normally occupied by osteoblasts. The data support the osteogenic differentiation of human muscle-derived cells in response to the secreted BMP-2.
tions of cells within human skeletal muscle and that certain populations are more responsive to BMP-2 than others. For clinical purposes, however, the preplating technique adds additional technical complexity to the ex vivo approach. Therefore the various cell populations were pooled to recreate a mixed population of human muscle-derived cells for use in the in vivo experiment. The mixed population was equivalent to that which would be isolated for clinical applications using simple cell-culture methods without using the ppl technique. Included in this mixed population are fibroblasts unresponsive to BMP-2. Therefore the cell population used in the in vivo experiment can be easily and reproducibly isolated in any laboratory with basic cellculture equipment. With the advancement of cell-isolation techniques, discrete populations of human muscle-derived cells may be used for specific applications, for example, osteocompetent cells from ppl 3 to populate allograft bone or BMP-2-secreting cells from ppl 1 to promote bone ingrowth into the femoral stem.
The in vivo data showed that the ectopic bone formed within the first two weeks after injection and tended not to enlarge thereafter. This result was expected, given the use of an adenoviral vector. The adenovirus genome, containing the BMP-2 gene, remains as an episome within the nuclei of transduced cells. Therefore, the BMP-2 gene is not integrated into the genome of transduced cells and is not passed on to daughter cells. Consequently, cell division results in the eventual loss of the BMP-2 gene and cessation of the secretion of BMP-2. Alternative approaches include the use of retroviral vectors (gene integration into the genome) to achieve long-term gene expression. Future gene therapy approaches will investigate the use of regulated vectors in which the gene expression may be controlled by pharmacological agents such as doxycycline. Previous studies have described methods of BMP-2 gene therapy. [3] [4] [5] [6] [7] [8] [10] [11] [12] 20 21 Because retrovirus infects only actively-dividing cells, the labelled cells in the in vivo experiment represented actively-dividing cells at the time of transduction. In order to label the injected cells persistently, a retroviral vector was chosen. It is not possible from our study to determine the fate of any non-dividing cells at the time of transduction and, more importantly, to eliminate the possibility of the participation of non-transduced donorderived cells (white, not blue) within the osteogenic and cartilage tissue (Fig. 5) . The ELISA data indicate that 2 ϫ 10 6 AdBMP-2-transduced cells secrete between 444 and 2551 ng of BMP-2, which is sufficient to lead to the formation of ectopic bone in vivo. These data were consistent with those determined for other cell types 11 and are 10 to 100 times less than the quantities of exogenous rhBMP-2 required in previous studies 22 to induce in vivo formation of bone. Finally, our study has shown that primary human skeletal muscle-derived cells can be successfully used in ex vivo gene delivery applications of BMP2. Mesenchymal stem cells are resting cells capable of differentiation into multiple tissue lineages (muscle, bone, cartilage, ligament, etc). 23 Previous studies support the existence of osteoprogenitors in the skeletal muscle of a number of species, including man. 5, 12, 13, 21, 24, 25 Our study contributes further evidence that human muscle-derived cells can differentiate into an osteogenic lineage. However, we found no labelled cells in cartilage lacunae of the ectopic bone (Fig. 5a) . It is not possible to determine from our study whether human skeletal-muscle-derived cells have chondrogenic potential since this study was not designed specifically to address that issue. We recently identified a new population of muscle-derived stem cells from murine skeletal muscle which express markers of haematopoietic stem cells and differentiate into osteogenic and myogenic lineages in vitro and in vivo. 5 The existence of a similar population of cells within human skeletal muscle is consequently under investigation. BMP-based investigations of gene therapy have previously focused on animal cells. Our study shows that human skeletal-muscle-derived cells can be successfully used in ex vivo gene therapy to deliver BMP-2. Human skeletal muscle, obtained during the primary operation and containing osteoprogenitors, is an attractive source of tissue for the orthopaedic surgeon. Human skeletal muscle is readily available, adequate numbers of cells may be obtained from this tissue in a timely fashion, and it contains cells responsive to BMP-2.
Investigations into the clinical applications of musclecell-based ex vivo BMP-2 gene delivery reconstructions of bone defects, nonunion, spinal fusions and implant stabilisation are ongoing as is the development of alternative viral and non-viral vectors.
